Both FD2 and FD3 contained albumin-binding domains to improve tumor retention and therapeutic efficacies, with the latter bearing additional MVK sequence to accelerate clearance of the radioligand when circulated to the kidneys. This evidence concerns the gene ALB and neoplasm.